Clinical and Experimental Dermatology最新文献_第2页

Intralesional sodium thiosulfate is an effective treatment for nonuraemic calciphylaxis. 局部注射硫代硫酸钠是治疗非尿毒性钙化的有效方法。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf254

Wen Hao Tan, Joel Hua Liang Lim

引用次数: 0

'Folie à SoMe?' Patient-centred delusional infestation care should consider the role of social media. “follie SoMe?”以患者为中心的妄想感染护理应考虑社交媒体的作用。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf269

Aparna Potluru, Yasmin Nikookam, Jonathan Guckian

引用次数: 0

Granulomatous reaction to red tattoo pigment successfully treated with topical allopurinol. 用局部别嘌呤醇成功治疗红色纹身色素肉芽肿反应。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf257

Marcial Álvarez-Salafranca, Itziar Muelas-Rives, Iranzu Barandika-Urrutia, Ignacio Hernández-Aragües, María Carmen Gómez-Mateo

引用次数: 0

Atopic dermatitis and obsessive-compulsive disorder: a systematic review. 特应性皮炎与强迫症：系统综述。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf259

Sheila Sharifi, Isabella J Tan, Mohammad Jafferany

{"title":"Atopic dermatitis and obsessive-compulsive disorder: a systematic review.","authors":"Sheila Sharifi, Isabella J Tan, Mohammad Jafferany","doi":"10.1093/ced/llaf259","DOIUrl":"10.1093/ced/llaf259","url":null,"abstract":"Atopic dermatitis (AD) is a prominent inflammatory skin disorder that significantly affects daily functioning and mental health in patients. Among its psychological repercussions, besides anxiety and depression, obsessive-compulsive disorder (OCD) has emerged. Multiple studies have indicated an increased risk of OCD in patients with AD. This systematic review aims to synthesize and evaluate the current literature on the association between AD and OCD, with particular attention to mechanisms linking disease and integrative treatment approaches. A search of the PubMed, PsycINFO and Web of Science databases was performed on 12 September 2024 to select peer-reviewed English-language studies relevant to our topic. Our results revealed the influences of demographic variables such as sex, age and atopic severity as being central to concomitant disease prevalence, with women and young adults having the highest risk of comorbidity. The complex interaction between the two disease states is thought to be a bidirectional relationship characterized by immunological, behavioural and genetic factors. Hence, an understanding of the underlying pathophysiology is necessary for comprehensive management. Patients may benefit from a multifaceted approach, including prescription of immunomodulatory agents and referral to psychiatry and psychology. Ultimately, we seek to inform clinical practice by advocating for interdisciplinary approaches to care and providing the framework for future investigations.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1968-1974"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life experience using topical chlormethine gel in the treatment of stage IA to IVA2 mycosis fungoides: a single-centre experience of 66 patients. 使用局部氮芥末凝胶治疗IA-IVA2期蕈样真菌病的实际经验：66名患者的单中心经验。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf265

Farrah S Bakr, Rita Entsua Mensah, Claire Lusted, Fiona Child, Bjorn Thomas, Sean Whittaker, Stephen Morris, Van Sim, E Mary Wain

引用次数: 0

Evaluating the quality and readability of online information about hidradenitis suppurativa: a systematic review. 评价化脓性汗腺炎在线信息的质量和可读性：一项系统综述。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf236

Marra Aghajani, Ericka Maye, Kate Burrell, Cindy Kok, John W Frew

{"title":"Evaluating the quality and readability of online information about hidradenitis suppurativa: a systematic review.","authors":"Marra Aghajani, Ericka Maye, Kate Burrell, Cindy Kok, John W Frew","doi":"10.1093/ced/llaf236","DOIUrl":"10.1093/ced/llaf236","url":null,"abstract":"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with considerable physical, psychological and social burdens. Despite increasing recognition, diagnostic delays remain common, often prompting patients to seek information online. In this systematic review, we evaluated the quality and readability of HS-related information across artificial intelligence (AI)-generated content, search--engine-derived resources and social media platforms. A comprehensive search of PubMed, Embase, Cochrane Library and Google Scholar identified 17 studies published between 2017 and 2024 that assessed HS-related online content using validated scoring tools and/or physician evaluation. More than 50% of studies rated online HS materials as variable in quality, with 36% rating them as moderate. Readability -assessments revealed that most resources exceeded the recommended sixth-grade to eighth-grade school level, limiting accessibility for patients. Social media platforms, particularly TikTok and YouTube, featured highly engaging but frequently inaccurate or anecdotal content, with physician-generated materials receiving lower engagement than nonmedical resources. These findings highlight the critical need for simplified, -evidence-based online resources to improve health literacy and support informed decision-making by patients with HS. The prevalence of misinformation, particularly regarding alternative treatments and pharmaceutical scepticism, underscores the urgent need to develop enhanced patient education strategies. Future efforts should focus on AI-driven readability improvements, clinician engagement in digital education and collaboration with social media platforms to ensure the availability of accessible, high-quality HS information.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1937-1944"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin surgery and cosmetic dermatology. 皮肤外科和美容皮肤科。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf251

Eimear Duff, Roisin Rynne, Cliona Feighery, Niamh Kearney

引用次数: 0

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. deucravacitinib治疗中重度斑块型银屑病的两项3期临床试验中PASI和PASI成分的结果

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf215

Mark Lebwohl, Melinda J Gooderham, Richard B Warren, Diamant Thaçi, Peter Foley, Alice B Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher E M Griffiths

{"title":"Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis.","authors":"Mark Lebwohl, Melinda J Gooderham, Richard B Warren, Diamant Thaçi, Peter Foley, Alice B Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher E M Griffiths","doi":"10.1093/ced/llaf215","DOIUrl":"10.1093/ced/llaf215","url":null,"abstract":"Deucravacitinib was significantly more effective than placebo in the 52-week, phase III POETYK PSO-1 and PSO-2 trials. This study further evaluated deucravacitinib efficacy compared with placebo in these trials based on Psoriasis Area and Severity Index (PASI) outcomes. Patients with moderate to severe plaque psoriasis received placebo or deucravacitinib 6 mg once daily. At week 16, patients crossed over from placebo to deucravacitinib. Patients treated with deucravacitinib had greater reductions from baseline in PASI within 1 week, with higher improvements observed compared with placebo at week 16. Patients who crossed over to deucravacitinib at week 16 achieved similar improvements at week 52 as patients treated continuously with deucravacitinib from day 1. Significantly higher proportions of patients treated with deucravacitinib achieved treat-to-target PASI thresholds (≤ 1, ≤ 2, ≤ 3, ≤ 4, ≤ 5), and significantly greater improvements were observed in each PASI component (body region: head, trunk, upper/lower extremities; plaque characteristics: erythema, induration, desquamation) compared with placebo at week 16.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"2030-2036"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies. 多中心，前瞻性，观察性临床登记的儿童和成人白癜风患者光疗，或新的局部/全身免疫调节疗法。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf249

Viktoria Eleftheriadou, Emma Rush, Lorraine Jacques

{"title":"Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies.","authors":"Viktoria Eleftheriadou, Emma Rush, Lorraine Jacques","doi":"10.1093/ced/llaf249","DOIUrl":"10.1093/ced/llaf249","url":null,"abstract":"Vitiligo is the most common depigmentation disorder, affecting around 1% of the population worldwide. Currently, no national or international registry for patients with vitiligo exists. Individual dermatologists maintain descriptive databases of such patients, which involve patients in one centre. However, such single-centre registries do not aim to establish the short- and long-term safety (pharmacovigilance) and effectiveness of vitiligo therapies. As an initial step for the development of a national UK registry for patients with vitiligo, development of a pilot multicentre registry in the UK is needed. This pilot study is being developed in collaboration with the British Association of Dermatologists. VIRTUAL-UK (VItiligo RegisTry for adUlts And chiLdren) assesses treatment effectiveness and safety as well as treatment impact on quality of life. The registry includes children and adults with vitiligo who receive phototherapy or novel topical and/or systemic immunomodulatory therapies. The VIRTUAL-UK registry will ultimately (i) inform treatment guidelines, (ii) provide pharmacogenetic and pharmacodynamic research data, (iii) help answer questions on skin cancer risk for patients with vitiligo who receive prolonged phototherapy courses, especially regarding high cumulative exposures in children with less deeply pigmented skin, and (iv) help to identify those patients likely to experience rapid disease progression. As a result, this registry will ultimately improve and personalize patient care. With novel topical and oral immunomodulatory therapies having just entered vitiligo clinical practice, the timing is ideal to harness the high-quality data collection offered by the UK National Health Service.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1982-1988"},"PeriodicalIF":2.8,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistent facial rash. 持续性面部皮疹。

IF 2.8 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-09-25 DOI: 10.1093/ced/llaf209

Hana El-Sbahi, Mohanad Aldiwani, Manisha Panchal, Marie O'Riordan, Karen E Harman

引用次数: 0